NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025
MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update.
“Our primary focus at Milestone is preparing for potential FDA approval of CARDAMYST (etripamil) nasal spray for the management of PSVT,” said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. “We believe that CARDAMYST has the potential to improve how PSVT is managed and positions Milestone to deliver meaningful value to patients, providers, and payors. Complementing our efforts in PSVT, we are very encouraged by clinician interest in the etripamil Phase 3 study in AFib-RVR which we are working toward commencing in the first half of 2025.”
Third Quarter and Recent Program Updates
CARDAMYST for patients with paroxysmal supraventricular tachycardia (PSVT)
Etripamil for patients with AFib-RVR
Corporate Updates
Third Quarter 2024 Financial Results
For further details on the Company’s financials, refer to the quarterly report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 12, 2024.
About Etripamil
Etripamil is Milestone’s lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and AFib-RVR. It is designed as a self-administered rapid response therapy for patients thereby bypassing the need for immediate medical oversight. If approved, etripamil is intended to provide health care providers with a new treatment option to enable on-demand care and patient self-management. This portable, self-administered treatment may provide patients with active management and a greater sense of control over their condition. CARDAMYST™ (etripamil) nasal spray, the conditionally approved brand name for etripamil nasal spray, is well studied with a robust clinical trial program that includes a completed Phase 3 clinical-stage program for the treatment of PSVT and Phase 2 trial for the treatment of patients with AFib-RVR.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone’s lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “continue,” “could,” “demonstrate,” “designed,” “develop,” “estimate,” “expect,” “may,” “pending,” “plan,” “potential,” “progress,” “will”, “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding: the timing and outcomes of future interactions with U.S. and foreign regulatory bodies, including the FDA, including the timing of the FDA’s review of the NDA; the ability of CARDAMYST to improve how PSVT is managed and position Milestone to deliver meaningful value to patients and providers; the timing of the commercial launch of etripamil for PSVT; and the timing, design and outcomes of our clinical trials, including our Phase 3 study in AFib-RVR. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, whether our future interactions with the FDA will have satisfactory outcomes; whether and when, if at all, our NDA for etripamil will be approved by the FDA; whether the FDA will require additional trials or data which may significantly delay and put at risk our efforts to obtain approval and may not be successful, the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of our clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, Russian hostilities in Ukraine and ongoing disputes in Israel and Gaza and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, and risks related the sufficiency of Milestone’s capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone’s filings with the U.S. Securities and Exchange Commission (SEC), including in its annual report on Form 10-K for the year ended December 31, 2023 and its quarterly report on Form 10-Q for the quarter ended September 30, 2024, under the caption “Risk Factors,” as such discussion may be updated from time to time by subsequent filings Milestone may make with the SEC. Except as required by law, Milestone assumes no obligation to update any forward looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Contact:
Kim Fox, Vice President, Communications, kfox@milestonepharma.com
Investor Relations
Chris Calabrese, ccalabrese@lifesciadvisors.com
Kevin Gardner, kgardner@lifesciadvisors.com
Milestone Pharmaceuticals Inc. Condensed Consolidated Statements of Loss (Unaudited) (in thousands of US dollars, except share and per share data) |
|||||||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||
Revenue | $ | — | $ | — | $ | — | $ | 1,000 | |||||||
Operating expenses | |||||||||||||||
Research and development, net of tax credits | 3,963 | 6,721 | 10,417 | 25,600 | |||||||||||
General and administrative | 3,742 | 4,227 | 12,741 | 12,561 | |||||||||||
Commercial | 1,911 | 4,412 | 6,596 | 10,137 | |||||||||||
Loss from operations | (9,616 | ) | (15,360 | ) | (29,754 | ) | (47,298 | ) | |||||||
Interest income | 1,080 | 1,120 | 3,260 | 2,921 | |||||||||||
Interest expense | (903 | ) | (841 | ) | (2,662 | ) | (1,697 | ) | |||||||
Net loss and comprehensive loss | $ | (9,439 | ) | $ | (15,081 | ) | $ | (29,156 | ) | $ | (46,074 | ) | |||
Weighted average number of shares and pre-funded warrants outstanding, basic and diluted | 66,190,302 | 42,973,160 | 60,856,495 | 42,920,620 | |||||||||||
Net loss per share, basic and diluted | $ | (0.14 | ) | $ | (0.35 | ) | $ | (0.48 | ) | $ | (1.07 | ) | |||
Milestone Pharmaceuticals Inc. Condensed Consolidated Balance Sheets (Unaudited) (in thousands of US dollars, except share data) |
|||||||
September 30, 2024 | December 31, 2023 | ||||||
Assets | |||||||
Current assets | |||||||
Cash and cash equivalents | $ | 12,799 | $ | 13,760 | |||
Short-term investments | 63,620 | 52,243 | |||||
Research and development tax credits receivable | 837 | 643 | |||||
Prepaid expenses | 2,523 | 3,178 | |||||
Other receivables | 1,211 | 3,208 | |||||
Total current assets | 80,990 | 73,032 | |||||
Operating lease right-of-use assets | 1,515 | 1,917 | |||||
Property and equipment | 201 | 277 | |||||
Total assets | $ | 82,706 | $ | 75,226 | |||
Liabilities, and Shareholders’ Equity | |||||||
Current liabilities | |||||||
Accounts payable and accrued liabilities | $ | 4,676 | $ | 6,680 | |||
Operating lease liabilities | 582 | 546 | |||||
Total current liabilities | 5,258 | 7,226 | |||||
Operating lease liabilities, net of current portion | 1,002 | 1,457 | |||||
Senior secured convertible notes | 52,434 | 49,772 | |||||
Total liabilities | 58,694 | 58,455 | |||||
Shareholders’ Equity | |||||||
Common shares, no par value, unlimited shares authorized 53,327,908 shares issued and outstanding as of September 30, 2024, 33,483,111 shares issued and outstanding as of December 31, 2023 | 288,006 | 260,504 | |||||
Pre-funded warrants – 12,910,590 issued and outstanding as of September 30, 2024 and 9,577,257 as of December 31, 2023 | 53,076 | 48,459 | |||||
Additional paid-in capital | 38,112 | 33,834 | |||||
Accumulated deficit | (355,182 | ) | (326,026 | ) | |||
Total shareholders’ equity | 24,012 | 16,771 | |||||
Total liabilities and shareholders’ equity | $ | 82,706 | $ | 75,226 | |||
- Leading efficient care management for the elderly with unimpeded smartcare https://img.hankyung.com/pdsdata/pr.hankyung.com/uploads/2024/11/image01-1.png SEOUL, South Korea, Nov.…
- Attruby is the first and only approved product with aspecifying near-complete stabilization…
PALO ALTO, Calif., Nov. 22, 2024 /PRNewswire/ -- Aulisa® Medical USA, Inc., a leader in…
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB:…
3,250 InsuJet Starter Packs Being Delivered to Pharmacies Across CanadaToronto, Ontario--(Newsfile Corp. - November 22,…